Breaking News

Celltrion Launches Avtozma IV Formulation in the U.S.

Avtozma was FDA-approved in January 2025 to treat the same conditions as the reference product Actemra (tocilizumab).

By: Rachel Klemovitch

Assistant Editor

Celltrion, Inc. announced that Avtozma (tocilizumab-anoh) intravenous (IV) formulation is now available to patients in the United States. Avtozma IV is approved for all same indications as the reference product Actemra  (tocilizumab), including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (PJIA), systemic juvenile idiopathic arthritis (SJIA), coronavirus disease (COVID-19), and cytokine release syndrome (CRS). Avtozma IV will be availab...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters